Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739722 · ClinicalTrials.gov registry record · NA
Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
A NA study, sponsored by Geneoscopy.
- Completed
- Registry status
- NA
- Development phase
- 14,263
- Enrollment target
NCT04739722: Completed NA study, sponsored by Geneoscopy.
NCT04739722 is a NA study that has completed, run by Geneoscopy. The registered enrollment target is 14,263 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (917% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04739722, a NA study, has completed, sponsored by Geneoscopy.
- COMPLETED
- Registry status
- NA
- Development phase
- 14,263 participants
- Enrollment target
Study Summary
This study was a prospective analysis conducted by Geneoscopy Inc. to evaluate the ColoSense test, which is a multi-target stool RNA test for colorectal cancer screening.
Interventions
- DIAGNOSTIC_TEST ColoSense
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,263 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2024-01-31 |
| Phase | NA |
What the finished NCT04739722 record still lists
NCT04739722 is an interventional study that assigns participants to a tested intervention. Its 14,263 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (917% higher).
The record links to 0 conditions, and to 1 intervention - of which ColoSense is the first listed.
NCT04739722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04739722 about?
NCT04739722 is a clinical study titled "Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study". This study was a prospective analysis conducted by Geneoscopy Inc. to evaluate the ColoSense test, which is a multi-target stool RNA test for colorectal cancer screening.
What is the current status of trial NCT04739722?
This trial is currently completed. It is a NA study. The enrollment target is 14,263 participants. The study started on 2021-04-12. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT04739722?
The interventions under investigation include: ColoSense (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04739722?
This trial is sponsored by Geneoscopy, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04739722's enrollment target sits among peer trials
14,263 13th of 2000 higher than 1,988 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT06849869 · 14,820 participants · NA
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI